Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis : a multicentre and retrospective study
López-Medina, Clementina (Universidad de Córdoba)
Calvo-Gutiérrez, Jerusalem (Universidad de Córdoba)
Ábalos-Aguilera, M. Carmen (Universidad de Córdoba)
Cepas, Francisco (Universidad de Córdoba)
Plasencia-Rodríguez, Chamaida (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Martínez-Feito, Ana (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Balsa, Alejandro (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Faré-García, Regina (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Juan-Mas, Antoni (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Ruiz-Esquide, Virginia (Hospital Clínic i Provincial de Barcelona)
Sainz, Luis (Institut de Recerca Sant Pau)
Díaz Torne, César (Institut de Recerca Sant Pau)
Godoy-Navarrete, Francisco Javier (Hospital Universitario de Jaén)
Añón-Oñate, Isabel (Hospital Universitario de Jaén)
Mena-Vázquez, Natalia (Instituto de Investigación Biomédica de Málaga)
Manrique-Arija, Sara (Universidad de Málaga)
Moreno-García, Marina Soledad (Hospital Universitario Miguel Servet (Saragossa))
Ortega-Castro, Rafaela (Universidad de Córdoba)
Escudero-Contreras, Alejandro (Universidad de Córdoba)

Data:	2024
Resum:	Objective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cutoff: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. Results A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2. 3 (95% CI 1. 2 to 4. 3), or ETA (HR 2. 8 (95% CI 1. 5 to 5. 2). No differences were found between groups in patients with <200 UI/mL. Conclusions CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Antibodies, Monoclonal ; Arthritis, Rheumatoid ; Certolizumab Pegol ; Etanercept ; Humans ; Retrospective Studies ; Rheumatoid Factor ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors
Publicat a:	RMD Open, Vol. 10 Núm. 1 (23 2024) , p. e003975, ISSN 2056-5933

DOI: 10.1136/rmdopen-2023-003975
PMID: 38395455

9 p, 1.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats